Nucana Plc ADR (NCNA) Stock Price, Quote & News

Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside...

Industry: Biotechnology

Sector: Healthcare

Phone: 44 13 1357 1111

Website: www.nucana.com

Address:

3 Lochside Way, Edinburgh, United Kingdom

ChickenClaw Apr. 29 at 3:41 PM

$NCNA Up 60% In Last Month...Keep Buying The Dips On Its Way Up.

0 · Reply

GreenEnergy1 Apr. 29 at 3:35 PM

$NCNA What’s the excuse the Bulls are going to make now.… Been waiting months and months for their expected 🚀 Nucana continues to be a 💩 and no one can disprove that! Buyer Beware…

0 · Reply

ChickenClaw Apr. 29 at 3:10 PM

$NCNA My Level 2 Is Showing 70,000 Shares Traded At $2.18....IS That More Insider Buying?

1 · Reply

cycloon Apr. 29 at 1:59 PM

$NCNA

0 · Reply

GreenEnergy1 Apr. 29 at 10:58 AM

$NCNA Same Garbage, Different Day!

1 · Reply

TVanda00 Apr. 28 at 8:03 PM

$NCNA Green monthly candles with short wicks seem to precede a higher price the subsequent month.

0 · Reply

GreenEnergy1 Apr. 28 at 6:29 PM

$NCNA on

0 · Reply

checkthef Apr. 28 at 5:22 PM

$NCNA nucana was awarded a patent in malasya last friday. IP getting stronger.

1 · Reply

ChickenClaw Apr. 28 at 2:13 PM

$NCNA Next Leg Coming Up....Get In Before This Sale Is Gone.

1 · Reply

bills7765 Apr. 28 at 12:47 PM

$NCNA correction. Was brought to my attention an error in my posting yesterday. It was not a new position by Glass, merely updated filing. Most likely had books done early and just filed. I be sure to check the delta in future for change. My apologies for the bad info. Ty to

1 · Reply

NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

Jan 6, 2026, 8:00 AM EST - 4 months ago

NuCana Appoints Theresa Bruce as Chief Operating Officer

Dec 10, 2025, 8:00 AM EST - 5 months ago

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

Nov 13, 2025, 4:01 PM EST - 5 months ago

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 8:00 AM EST - 6 months ago

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

Sep 5, 2025, 8:00 AM EDT - 8 months ago

NuCana Compliant with All Nasdaq Continued Listing Criteria

Sep 3, 2025, 8:00 AM EDT - 8 months ago

NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025

Aug 20, 2025, 4:05 PM EDT - 8 months ago

NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 1, 2025, 4:05 PM EDT - 9 months ago

NuCana Announces ADS Ratio Change

Jul 21, 2025, 8:05 AM EDT - 10 months ago

NuCana Cancels All Outstanding Series A Warrants Following Strategic ATM Execution

Jul 11, 2025, 10:30 AM EDT - 10 months ago

NuCana Announces Plan to Implement ADS Ratio Change

Jun 2, 2025, 4:01 PM EDT - 11 months ago

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

Mar 20, 2025, 4:01 PM EDT - 1 year ago

NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Feb 10, 2025, 7:00 AM EST - 1 year ago

Aurion Biotech Appoints Donald Munoz as Chief Financial Officer

Nov 25, 2024, 7:00 AM EST - 1 year ago

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 11, 2024, 7:00 AM EST - 1 year ago

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Oct 4, 2024, 12:03 PM EDT - 1 year ago

Baillie Gifford's Strategic Acquisition of NuCana PLC Shares

Sep 25, 2024, 4:01 PM EDT - 1 year ago

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

$NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024$

Sep 14, 2024, 3:01 AM EDT - 1 year ago

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

Aug 29, 2024, 4:01 PM EDT - 1 year ago

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

Aug 15, 2024, 4:01 PM EDT - 1 year ago

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

May 30, 2024, 8:36 AM EDT - 2 years ago

NuCana to Present at the Jefferies Global Healthcare Conference

May 21, 2024, 8:00 AM EDT - 2 years ago

NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit

May 16, 2024, 4:01 PM EDT - 2 years ago

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

May 1, 2024, 4:01 PM EDT - 2 years ago

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 9, 2024, 4:30 PM EDT - 2 years ago

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

Mar 20, 2024, 4:01 PM EDT - 2 years ago

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 2 years ago

NuCana to Present at TD Cowen's 44th Annual Health Care Conference

Nov 16, 2023, 4:01 PM EST - 2 years ago

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 10, 2023, 4:01 PM EST - 2 years ago

NuCana Announces Listing Transfer to Nasdaq Capital Market

Nov 8, 2023, 4:01 PM EST - 2 years ago

NuCana to Present at the Jefferies London Healthcare Conference

Nov 1, 2023, 4:01 PM EDT - 2 years ago

NuCana to Participate in the Truist Securities 2023 BioPharma Symposium

Oct 16, 2023, 7:00 AM EDT - 2 years ago

NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Oct 13, 2023, 12:30 PM EDT - 2 years ago

NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Sep 18, 2023, 8:00 AM EDT - 2 years ago

NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Aug 16, 2023, 4:01 PM EDT - 2 years ago

NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update

Jun 1, 2023, 8:00 AM EDT - 3 years ago

NuCana to Present at the Jefferies Healthcare Conference

May 17, 2023, 4:01 PM EDT - 3 years ago

NuCana Reports First Quarter 2023 Financial Results and Provides Business Update

May 12, 2023, 4:01 PM EDT - 3 years ago

NuCana Announces Receipt of Nasdaq Notice

Apr 14, 2023, 8:00 AM EDT - 3 years ago

NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action

Apr 4, 2023, 4:01 PM EDT - 3 years ago

NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Mar 24, 2023, 4:30 PM EDT - 3 years ago

Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana's ‘190 Patent is Not Valid

Feb 28, 2023, 8:00 AM EST - 3 years ago

NuCana to Participate in Two Upcoming Investor Conferences

Jan 6, 2023, 4:01 PM EST - 3 years ago

NuCana Announces Receipt of NASDAQ Notice

Nov 16, 2022, 4:01 PM EST - 3 years ago

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

Oct 26, 2022, 7:00 AM EDT - 3 years ago

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

Sep 12, 2022, 10:45 AM EDT - 3 years ago

NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

Sep 6, 2022, 8:00 AM EDT - 3 years ago

NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022

Aug 31, 2022, 8:00 AM EDT - 3 years ago

NuCana to Participate in Citi's 17th Annual BioPharma Conference

Aug 17, 2022, 4:01 PM EDT - 4 years ago

NuCana Reports Second Quarter 2022 Financial Results and Provides Business Update

ChickenClaw Apr. 29 at 3:41 PM

$NCNA Up 60% In Last Month...Keep Buying The Dips On Its Way Up.

0 · Reply

GreenEnergy1 Apr. 29 at 3:35 PM

$NCNA What’s the excuse the Bulls are going to make now.… Been waiting months and months for their expected 🚀 Nucana continues to be a 💩 and no one can disprove that! Buyer Beware…

0 · Reply

ChickenClaw Apr. 29 at 3:10 PM

$NCNA My Level 2 Is Showing 70,000 Shares Traded At $2.18....IS That More Insider Buying?

1 · Reply

cycloon Apr. 29 at 1:59 PM

$NCNA

0 · Reply

GreenEnergy1 Apr. 29 at 10:58 AM

$NCNA Same Garbage, Different Day!

1 · Reply

TVanda00 Apr. 28 at 8:03 PM

$NCNA Green monthly candles with short wicks seem to precede a higher price the subsequent month.

0 · Reply

GreenEnergy1 Apr. 28 at 6:29 PM

$NCNA on

0 · Reply

checkthef Apr. 28 at 5:22 PM

$NCNA nucana was awarded a patent in malasya last friday. IP getting stronger.

1 · Reply

ChickenClaw Apr. 28 at 2:13 PM

$NCNA Next Leg Coming Up....Get In Before This Sale Is Gone.

1 · Reply

bills7765 Apr. 28 at 12:47 PM

1 · Reply

bills7765 Apr. 28 at 12:23 PM

$NCNA will see if high dtc tripped algos today

0 · Reply

bills7765 Apr. 28 at 12:42 AM

$NCNA 14.5 days to cover now per

0 · Reply

TVanda00 Apr. 28 at 12:21 AM

$NCNA Hard not to forget what happened on Oct 7 of last year around a catalyst time. Price soared ONLY in the over night (dark pool) hours only to drop before premarket opened, leaving retail confused and behind.

2 · Reply

bills7765 Apr. 27 at 11:05 PM

$NCNA they snuck in. Insiders and institutions are loaded filed. Now we have confirmation they were soaking up shorts and sells. People are shorting right into institutional buys. Or they may be shorting and recovering in dark pools. Either or I think really good things happening behind the scenes.

0 · Reply

bills7765 Apr. 27 at 10:59 PM

$NCNA this looks like a rush filing. We are friggin cooking. Thats a 15k shares buy on 4/23. Telling you guys something going to happen soon. Sorry of its not showing. Check fintel. Buys.

6 · Reply

FlyingTargets Apr. 27 at 8:33 PM

$NCNA $CABA VI

0 · Reply

FlyingTargets Apr. 27 at 7:47 PM

$NCNA $AFRM rally

0 · Reply

Spc_baller Apr. 27 at 7:27 PM

$NCNA testing patience

0 · Reply

TVanda00 Apr. 27 at 4:13 PM

$NCNA $2.49 today ?

1 · Reply

cycloon Apr. 27 at 2:18 PM

$NCNA NCNA can also break out at any moment.

0 · Reply

cycloon Apr. 27 at 1:49 PM

$NCNA As of early 2026, NuCana (NCNA) is advancing its ProTide therapeutics pipeline, highlighting positive data for NUC-7738 in combination with PD-1 inhibitors for resistant cancers. The company reported in March 2026 that cash reserves are expected to fund operations into 2029. Key developments include new patents in China and a strengthened management team.

0 · Reply

FickleFin Apr. 27 at 11:40 AM

$NCNA 📉 same ole same ole. Time decay while invested lose $$$.

0 · Reply

Market Cap	8.57M
Revenue (ttm)	0.00
Net Income (ttm)	-38.71M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	23,655
Avg Vol	41,628
Day's Range	N/A - N/A
Shares Out	4.16M
Stochastic %K	44%
Beta	1.79
Analysts	Strong Buy
Price Target	$25.00